Market Research Reports

  Liquid biopsy is an essential part of medical decision-making and aids in obtaining information for a wide range of treatment dissemination. Liquid biopsy has a crucial role in the precision medicine approach, as it confirms the safe and effective application of targeted therapeutics. The global   liquid biopsy market    was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine.   Liquid biopsy can be used as a better alternative for treatment and recurrence monitoring as it overcomes invasive biopsy challenges of taking a tumor sample again and again during the course of the treatment. Next-generation sequencing (NGS) is a DNA sequencing technology that has transformed genomi...

  Liquid biopsy has a critical role in the precision medicine approach, as it confirms the safe and effective application of targeted therapeutics. A liquid biopsy helps physicians to analyze tumor-related information through a simple blood test. As researchers are generating data that have the potential to lead to unprecedented biological insight, albeit at the cost of the greater complexity of data analysis. Increasing investments in R&D of liquid biopsy products and services and various research fundings is one of the major opportunities in the global liquid biopsy market. The global  liquid biopsy market   was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine. Impact of COVID-19 The cur...